Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors

A method of treating or delaying progression of cancer in an individual, the method comprising administering to the individual an effective amount of a PD-1 axis binding antagonist and an agent that inhibits and/or blocks the interaction of CD226 with TIGIT, wherein the agent is an inhibitory antibody or antigen-binding fragment thereof, wherein the inhibitory antibody or antigen-binding fragment thereof is an anti-CD226 antibody or antigen-binding fragment thereof.

A method of increasing, enhancing, or stimulating an immune response or function in an individual, the method comprising administering to the individual an effective amount of a PD-1 axis binding antagonist and an agent that inhibits and/or blocks the interaction of CD226 with TIGIT, wherein the agent is an inhibitory antibody or antigen-binding fragment thereof, wherein the inhibitory antibody or antigen-binding fragment thereof is an anti-CD226 antibody or antigen-binding fragment thereof.

A method for treating or delaying progression of a viral infection in an individual, the method comprising administering to the individual an effective amount of a PD-1 axis binding antagonist and an agent that inhibits and/or blocks the interaction of CD226 with TIGIT, wherein the agent is an inhibitory antibody or antigen-binding fragment thereof, wherein the inhibitory antibody or antigen-binding fragment thereof is an anti-CD226 antibody or antigen-binding fragment thereof.